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ABSTRACT  
Standard of care for cancer is commonly a combination of surgery with radiotherapy or 
chemoradiotherapy. However, in some advanced cancer patients this approach might still remain  
inefficient and may cause many side effects, including severe complications and even death. 
Oncolytic viruses exhibit different anti-cancer mechanisms compared with conventional therapies, 
allowing the possibility for improved effect in cancer therapy. Chemotherapeutics combined with 
oncolytic viruses exhibit stronger cytotoxic responses and oncolysis. Here, we have investigated the 
systemic delivery of the oncolytic adenovirus and paclitaxel encapsulated in extracellular vesicles 
(EV) formulation that, in vitro, significantly increased the transduction ratio and the infectious titer 
when compared with the virus and paclitaxel alone. We demonstrated that the obtained EV 
formulation reduced the in vivo tumor growth in animal xenograft model of human lung cancer. 
Indeed, we found that combined treatment of oncolytic adenovirus and paclitaxel encapsulated in EV 
has enhanced anticancer effects both in vitro and in vivo in lung cancer models. Transcriptomic 
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comparison carried out on the explanted xenografts from the different treatment groups revealed that 
only 5.3% of the differentially expressed genes were overlapping indicating that a de novo genetic 
program is triggered by the presence of the encapsulated paclitaxel: this novel genetic program might 
be responsible of the observed enhanced antitumor effect. Our work provides a promising approach 
combining anticancer drugs and viral therapies by intravenous EV delivery as a strategy for the lung 
cancer treatment.  
 
Key words: extracellular vesicles, oncolytic viruses, cancer therapy, drug delivery, paclitaxel, 
xenograft animal model, lung cancer 
 
 
INTRODUCTION 
 
Despite major advances in conventional cancer treatments with surgery, radiotherapy, chemotherapy,  
and their combination, the outcome is still partially ineffective against numerous cancer types, like 
lung cancer [1]. Lung cancer is highly invasive and rapidly metastasizing, often diagnosed at an 
advanced stage with poor prognosis and without efficient treatment options [2]. Given the poor 
survival rate of patients, new therapeutic strategies with systemic drug delivery are warranted. 
Oncolytic virotherapy is emerging as a promising and potential approach to treat cancer, and the 
approval of the first oncolytic virus, Imlygic (T-Vec, talimogene laherparepvec), in the Western 
world by US Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
provides new perspectives for improved treatment of cancer [3,4]. Indeed, its application can be 
particularly relevant for tumors without curative options, including metastatic lung cancers [1]. In 
oncolytic virus therapy, viruses are specifically engineered to preferentially infect, replicate in and 
kill cancer cells instead of normal cells where their normal functions are restricted [5–9]. Virus 
replication in tumor cells eventually leads to cell lysis, allowing the new virus progeny to spread to 
surrounding cells and even to distant metastases through circulation [10]. However, as a single 
therapeutic agent oncolytic adenoviruses have not been observed to efficiently destroy large tumor 
mass in patients [11,12]. Thus there is a need to enhance their antitumor efficacy by combining viral 
therapy with other anticancer agents[13–15]. Cisplatin has improved oncolysis of Herpes simplex 
virus type 1 (HSV-1) in non small cell lung cancer (NSCLC) [16]. Additionally, combination of 
cisplatin with adenovirus facilitated the replication of the virus and significantly reduced the tumor 
progression [17]. Enhanced effects have been also reported in a malignant pleural mesothelioma 
(MPM) with NV1066 (HSV-1 based virus) [18]. However, the use of oncolytic viruses as a potential 
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approach to treat cancer has also disadvantages [19]; the immune response will presumably limit 
ongoing viral replication and spread in cancer cells. Administered viruses will be detected by 
immune system and inactivated by neutralizing antibodies, decreasing its replication and efficacy. 
Additionally, given the intratumoral administration of oncolytic viruses [20–22], they are eligible 
only in injectable lesions and thus limiting the approach to treat many solid tumors. Systemic 
delivery of virus together with anticancer drugs would circumvent some of these limitations. 
Extracellular vesicles (EVs) are naturally occurring cargo delivery agents with the potential to be 
used as drug delivery vehicles [23,24] since they can transfer biological molecules even over long 
distances within the body [25]. The lipid membrane of EVs can protect the cargo from degradation 
by body fluids and further improved uptake by the target cells [26,27]. In recent studies, it has been 
shown to that oncolytic viruses can be delivered into the nucleus of tumorigenic cells by tumor 
microparticles while simultaneously avoiding the production of neutralizing antibodies and mediating 
the virus entry into cancer cells independently from the virus-specific receptor [28].  
In this study, we set to investigate whether it is possible to encapsulate the oncolytic adenovirus and 
chemotherapeutic agent into EVs in an attempt to utilize them as carriers for targeted drug delivery. 
The obtained formulations were tested in vitro in lung cancer cell line and subsequently in vivo in 
lung cancer xenograft animal model using both intra tumor (it) and intra venous (iv) injections. 
Abraxane (paclitaxel, albumin-bound nanoparticle formulation) and EVs without encapsulated virus 
and/or drug were used as control samples. We found that the systemic delivery of both oncolytic 
virus and paclitaxel encapsulated in EVs resulted in improved drug efficacy and reduced off-target 
toxicity.  
 
 
MATERIALS AND METHODS 
 
Cell culture 
A549 human lung cancer cell line was purchased from the American Type Culture Collection (ATCC, 
USA). The cells were cultured at 37 °C and 5 % CO2 in Dulbecco’s modified eagle medium (DMEM, 
Lonza, Switzerland) supplemented with 10 % fetal bovine serum (FBS, Gibco Laboratories, USA), 
1 % of 100 u/mL penicillin/streptomycin (Gibco Laboratories) and 1% L-glutamine (Gibco 
Laboratories).  PNT2 (European Collection of Authenticated Cell Cultures, ECACC, UK) human 
prostate cell line was purchased from Sigma-Aldrich. The cells were cultured at 37 °C and 5 % CO2 
in RPMI 1640 (Gibco Laboratories) supplemented with 10 % FBS (Gibco Laboratories), 1 % of 100 
u/mL penicillin/streptomycin (Gibco Laboratories) and 2% L-glutamine (Gibco Laboratories). The 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
prostate cancer cell line PC-3 (ATCC), was cultured at 37 °C and 5 % CO2 in Ham’s F-12K 
(Kaighn’s) basal medium (Gibco Laboratories) supplemented with 10 % FBS (Gibco Laboratories) 
and 1 % of 100 u/mL penicillin/streptomycin (Gibco Laboratories).  
 
Oncolytic virus  
Ad5D24-CpG, was generated according to standard protocols [29] by recombining a CpG-rich 
shuttle plasmid (pTHSN-CpG1) with a plasmid containing the 24 adenovirus backbone. Viral stocks 
were expanded in human lung cancer cell line A549 and purified on cesium chloride gradients. The 
viral particle concentration was determined by OD260-reading and standard TCID50 (tissue culture 
infectious dose 50) assay was performed to determine infectious particle titer. Virus was 
characterized by PCR and restriction enzyme analysis Ad5D24-RFP, expressing a red fluorescent 
protein (RFP) was kindly provided by Dr. Masataka Suzuki from Baylor College of Medicine 
(Houston, TX;[30]). 
 
 
Paclitaxel (PTX) solutions 
 
A 50 mM stock solution of Paclitaxel (PTX; Selleck Chemicals) was prepared by dissolving PTX 
into di-methyl sulfoxide (DMSO) (Sigma- Aldrich). This was used as the stock solution in A549 cell 
experiments as well as in EV-encapsulation of PTX.  Abraxane was provided for us by the Hospital 
Pharmacy of the Helsinki University Hospital based on the prescription of MD A. Mäkitie, School of 
Medicine, University of Helsinki, Finland. A stock suspension of Abraxane (Albumin-PTX 
conjugate, Celgene, USA) was prepared by suspending the powder, corresponding to 100mg of PTX, 
in phosphate buffer saline (PBS, Lonza) to a final volume of 8.5 mL, resulting in 11.76 mg/mL of 
PTX. This stock was then further diluted in PBS to produce the solutions used in the in vivo animal 
experiments exclusively. 
 
Production of Extracellular vesicles (EV) and PTX loaded EVs formulations 
In order to produce EVs 2.6 x 106 A549 cells were plated into T-175 flask in medium supplemented 
with 5 % FBS. The FBS growth media was ultra-centrifuged overnight (110 000 x g at 4°C for 18 
hours, Optima LE-80K ultracentrifuge, rotor type 50.2, Beckman Coulter) to remove EVs present in 
serum. Cells were cultured at 37 °C and 5 % CO2 until cytopathic effect was seen, where upon the 
media was collected.  
EVs were isolated from the conditioned medium using differential centrifugation. First the 
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conditioned medium was centrifuged at 500 x g in 4°C for 10 minutes to pellet cells (Allegra X-15R 
Centrifuge, Beckman Coulter). Then, the supernatant was collected and ultra-centrifuged for 2 hours 
at 100 000 x g in 4°C, using Optima L-80 XP ultra-centrifuge (Beckman Coulter) with rotor SW32Ti 
(Beckman Coulter). The supernatant was aspirated and EV- containing pellets containing re-
suspended in PBS (Lonza) 100 μL and stored at - 80 °C.  
PTX-loaded EVs were prepared as previously described by us [23] by incubating 1x108-5x109  EVs 
in 1 mL of 5 μM PTX-DPBS solution for in vitro samples and 10 μM PTX-DPBS solution for in vivo 
samples, for 1 hour at 22 °C. Next, the samples were centrifuged at 170 000 x g for 2 hours to pellet 
the EVs. The supernatant containing unbound PTX was removed, and the EV-pellet was washed by 
suspending it in DPBS and pelleting it again at 170 000 x g. 
Production of EV-Virus and EV-Virus-PTX formulations 
In order to produce EV-encapsulated virus (EV-Virus), 2.6 x 106 of A549 cells were infected with 
with 10 viral particles/cell of Ad5D24CpG and were cultured at 37 °C and 5 % CO2  . .  48 hours later 
when most of the cells were detached from the culture flask, the culture media were collected for EV-
Virus isolation using differential centrifugation. First the conditioned medium was centrifuged at 500 
x g and 4°C for 10 minutes, to separate the cells (Allegra X-15R Centrifuge, Beckman Coulter). Then, 
the supernatant containing EV-Virus was collected and ultra-centrifuged for 2 hours at 100 000 x g 
and 4°C, using Optima L-80 XP ultra-centrifuge (Beckman Coulter) with rotor SW32Ti (Beckman 
Coulter). The supernatant was aspirated and pellets containing EV-Virus re-suspended in PBS 100μL 
and stored at - 80 °C.  EV-Virus samples were incubated in 100 mM NaOH at room temperature for 
20 minutes in order to inactivate any free not EV encapsulated virus present. Free virus used as 
controls was always inactivated for each experiment performed as previously reported [31]. Samples 
were subsequently neutralized by the addition of HCl 0.1 M.  
To generate EV-Virus-PTX, the EV-Virus formulation was incubated in a 10µM PTX solution, 
prepared by diluting 10 mM PTX in DMSO with PBS with the ratio of 1:1000. Incubation was 
carried out at RT with mixing for 1 hour. Samples were then centrifuged at 150 000 x g for 2 hours at 
RT, in order to pellet EV-Virus-PTX. The washing procedure was repeated using PBS as diluent. The 
final EV-Virus-PTX pellet was re-suspended in 100 μL of PBS and stored at -80 °C. 
 
 
Quantification of PTX present in EV-Virus-PTX  
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50 µL of 1.5 x 1010 EV-Virus-PTX/mL as well as supernatant from the second washing step 
associated with removal of free PTX, to enable validation of the washing procedure, was processed 
for ultra performance liquid chromatography (UPLC, Acquity UPLC System) using a Cortecs UPLC 
C18+ column, 2.1x50 mm, particle size 2.7 µm (Waters, USA). Additionally, a 10 µM PTX solution 
was prepared, and used as a control for sample processing. Sodium dodecyl sulfate (SDS) was added 
to samples to a final concentration of 5 % (w/v) in order to lyse EV-Virus PTX. Vortexing was 
followed by incubation at RT for 1 hour. Acetonitrile was then added to a final concentration of 75 % 
(v/v) and samples vortexed. Precipitated proteins were pelleted by centrifugation at 10000 x g for 5 
minutes at RT. The supernatant was analyzed by UPLC using gradient flow of acetonitrile from 30 % 
to 80 % in phosphate buffer, pH=2, at 30 °C within 3 minutes. Detection and quantification of PTX, 
with a retention time of 1.7 minutes, was performed spectrophotometrically at the wavelength of 229 
nm by using a reference standard curve. 
 
 
 Size distribution analysis by nanoparticle tracking analysis (NTA)  
Size distribution and concentration of EV, EV-Virus and EV-Virus-PTX formulations were analyzed 
by NTA using Nanosight model LM14 (Nanosight) equipped with blue (404 nm, 70 mV) laser and 
sCMOS camera. The samples containing virus were incubated at +95 °C for 10 minutes in order to 
inactivate the viruses. NTA was performed for each sample by recording three 90 seconds videos, 
subsequently analyzed using NTA software 3.0 (Nanosight). The detection threshold was set to level 
5 and camera level to 15. 
 
Zeta potential analysis by electrophoretic light scattering  
The zeta potential was measured using ZetaSizer Nano (Malvern, UK). All the samples were diluted 
L of MilliQ H2O and injected with a 1 mL syringe in the capillary flow 
(DTS1070 folded capillary cell) for the measurement. An equilibration time of 120 seconds was set 
on the software to allow the samples to stabilize at 25°C inside the measurement chamber. Three 
parallel measurements were performed on each sample. 
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HIM microscopy  
For Helium Ion Microscopy, A549 cells were cultured to 70 % confluence in DMEM (Gibco 
Laboratories, USA) supplemented with heat inactivated 10 % FBS (Gibco Laboratories) and 100 
u/mL penicillin-streptomycin (Gibco Laboratories) on poly-L-lysin (Sigma Aldrich, Germany) glass 
coverslips. Cells in culture were infected with EV-Virus (5x109/mL on 75 cm2 80% confluent cell 
culture) by replacing the cell culture medium with a solution containing EV-Virus in DMEM of 2 % 
FBS and 100 u/mL penicillin-streptomycin. After two hours incubation, EV-Virus solution was again 
replaced with DMEM of 10 % FBS and 100 /mL penicillin-streptomycin. Cells were fixed at 
different time points by replacing the EV-Virus solution with 2 % glutaraldehyde (GA, Merck, USA) 
in 0.1 M Sodium Cacodylate (NaCac ) buffer (pH 7.4). After GA fixation, the cells were washed 
twice with 0.1 M NaCac and further fixed with 1 % OsO4 in 0.1 M NaCac buffer (pH 7.4). After one 
hour in OsO4, cells were washed twice with 0.1 M NaCac buffer and chemically dried in an 
increasing EtOH concentration series of 50 %, 70 %, 96 %, and twice with 100 %. After 100 % EtOH, 
the cells were submerged in 98% hexamethyldisiloxane (Sigma Aldrich) and left to dry for overnight. 
After fixation and chemical drying, coverslips were mounted on stands and imaged with Orion 
NanoFab Helium Ion Microscope (Zeiss, Germany) using 30 kV acceleration voltage with beam 
current 0.2-1 pA. 
 
 
Transduction assay  
Cells were seeded at a density of 1x104 cells/well in 96-well plates and maintained under appropriate 
condition. On the following day cells were treated in triplicates with an oncolytic adenovirus 
Ad5D24Rfp encoding for the red fluorescent protein (10vp/cell) and control EVs (10 particles/cell), 
EV-Virus (10 particles/cell), EV-PTX (10 particles/cell, 5µM of PTX), EV-Virus-PTX (10 
particles/cell, 5µM of PTX) or Virus and PTX separately (Virus+PTX) (10 vp/cell, 5µM of PTX). 
EVs, EV-Virus and EV-Virus-PTX had the same doses of particles as virus alone (10 vp were 
calculated as 10 EV-particles per cell in the well). The cells were then imaged with EVOS FL 
fluorescence microscope at 8, 24 and 48 hours after the treatment in order to count the portion of 
cells expressing RFP. 
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Immunocytochemistry staining (ICC) 
The determination of the infectivity was based on the visual quantification of infected cells as 
previously described [32,33]. Cells were seeded at a density of 2x105 cells/well in 24 well plates, and 
maintained under appropriate condition in DMEM, completed with 5% FBS, 1% L-glutammine and 
1% of penicillin/streptomycin. All the chemicals were purchased from Gibco Laboratories. On the 
following day cells were treated with Virus (10vp/ce ll), Virus+PTX (10vp/cell and 5 M PTX 
solution), EV-Virus formulations (10 particles/cell) and EV-Virus-PTX formulations (10 
particles/cell, 5µM of PTX). 
Plates were centrifuged for 90 minutes with 1000 x g in 37  °C and incubated for 48 hours before 
staining at 37°C and 5% CO2.  48 hours following the incubation cells were fixed by adding 250 l of 
ice-cold methanol per well and incubated 15 minutes. Then cells were washed three times with PBS 
1%-BSA (Bovine serum albumin, 9048-46-8 Sigma-Aldrich) solution and incubated in the dark for 
one hour with 1st antibody, mouse monoclonal anti-hexon 1:2000 (Novus Biological, NB600-413). 
After the incubation time, cells were washed three times with PBS 1%-BSA and incubated in the 
dark for other 1 hour with 2nd antibody: Biotin-SP-conjugated goat anti-mouse 1:500 (Jackson 
Immuno Research, 115-065-062). After the incubation time, cells were washed three times with 
PBS1%-BSA and incubated in the dark for 30 minutes with extravidin-peroxidase (Sigma Aldrich, 
E2886). Finally cells were washed three times as indicated earlier and treated with Dab peroxidase 
substrate solution (Sigma Aldrich, A7284-50ML). To quench the reaction, cells were treated once 
with PBS. The detection of the infectious titer was performed using microscope EVOS, and each well 
was photographed with 5 pcs at 5 non-overlapping sites. The following formula was used to 
determine the infectious titer:  
 
Infectious titer: x  
Where x= number of infected (stainend cells) 
A(24 well)= 190 mm2 
A(field) = surface area of the field 
l= dilution  
v= volume of virus dilution applied per well 
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MTS cell viability assay  
A549, PNT2 and PC3 cells were seeded at a density of 1x104 cells/well in 96-well plates and 
maintained under appropriate condition. On the following day cells were treated in triplicates with 
Virus (10vp/cell), Virus+PTX (10vp/cell + 5 M PTX solution), control EVs (10 particles/cell), EV-
PTX (10 particles/cell, 5µM of PTX), EV-Virus formulations (10 particles/cell), EV-Virus-PTX 
formulations (10 particles/cell, 5µM of PTX). Cell viability was determined by MTS assay according 
to the manufacturer's protocol (Cell Titer 96 AQueous One Solution Cell Proliferation Assay; 
Promega, Nacka, Sweden). The absorbance was measured with a 96-wells plate spectrophotometer 
Varioskan Flash Multimode Reader (Thermo Scientific) at 490 nm. The experiments were 
independently performed three times with triplicates of each condition in each experiment 
 
Analysis of apoptotic and necrotic cells  
 
A549 cells were plated into 6 well plates, 2x105 cells/well. Cells were treated with an oncolytic 
adenovirus Ad5D24CpG 10 vp/cell, Virus+PTX (10vp/cell + 5 M PTX solution), control EVs (10 
particles/cell), EV-PTX (10 particles/cell, 5µM of PTX), EV-Virus formulations (10 particles/cell), 
EV-Virus-PTX formulations (10 particles/cell, 5µM of PTX). The amount of apoptotic and necrotic 
cells was measured after 24 hours post-treatment with a TACS Annexin V-FITC kit (Trevigen Inc., 
Gaitherburg, MD, US) and BD LSRII flow cytometer according to the manufacturer´s instruction. 
 
 
 
 
In vivo xenograft animal experiments 
FIRST DAY OF 
TREATMENT 
Day 0 
SECOND DAY OF 
TREATMENT 
Day 2 
THIRD DAY OF 
TREATMENT 
Day 4 
FOURTH DAY OF 
TREATMENT 
Day 15 
EVs  
(1x109particles/tumor) 
X X X 
Virus  
(1x108 vp/tumor) 
X X PBS 
Abraxane  
(10 mg of PTX/kg) 
PBS PBS X 
Virus+Abraxane 
(1x108 vp/tumor +10 
mg of PTX/kg) 
X X X 
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EV-Virus  
(1x108 particles/tumor 
+ 1x108 vp/tumor) 
X X PBS 
EV-Virus-PTX 
(1x108 particles/tumor 
including 1x108 
vp/tumor, and 10 mg 
of PTX/kg) 
X X X 
 
All the animal experiments performed under the ethical permission (ESAVI/10482/04.10.07/2015) of 
the National Laboratory Animal Board of Finland (Care and Use Committee) by Made Consulting 
Ltd Oy (Turku, Finland) in GLP level animal facility.  
Mice were obtained from Janvier Labs (Barrier 4E-1, France) at 4 weeks of age. The acclimatization 
period was 13 days prior to A549 cancer cell injections, the cell line was the same used for the in 
vitro cell experiments. The A549 cell line purity was tested using  by IDEXX BioResearch - 
IMPACT III panel  before inoculation and the cells viability of 99 % were detected 50 minutes prior 
to first inoculation and 90 % 20 minutes after the last inoculation using NucleoCounter NC-
200. Health status of the mice was monitored daily and as soon as signs of pain or distress were 
evident they were euthanized. For the efficacy experiment, human xenografts were established by 
injecting 1.5x106 A549 cells s.c. into the flanks of 6-week old female BALB/c nude mice. The 
treatment groups were as follows: Virus (n=6); Virus+Abraxane (n=6); Abraxane (n=6); EV (n=6) 
and EV-Virus (n=9); EV-Virus-PTX (n=9). Treatment groups were administered i.v (100 µl) and i.t 
(50 µl) to mice with tumors (one tumor per mouse about 5 mm in diameter). The dosing days were 0, 
2, and 4 for Virus (according to previous protocols [29]) and EV-Virus; 0 and 15 for Abraxane as 
previously reported [34] ; 0, 2, 4 and 15 for EV and EV-Virus-PTX (table above and the 
Supplementary Table 1). The equation: 0.52 x length x (width)2, was used to calculate the tumor 
volumes to study the efficacy of the used EV-formulations. However, the average diameter of 15 mm 
was used as a limit to euthanize mice.  Tumors, livers and spleens from each mouse were collected 
for histopathological examinations. 
 
Quantitative PCR 
qPCR for adenovirus E4 copy number was carried out according to the protocol previously described 
[35] (primer FW:50-GGA GTG CGC CGA GAC AAC-30, primer RV: 50-ACT ACG TCC GGC 
GTT CCA T-30, probe E4: 50-(6FAM)-TGG CAT GAC ACT ACG ACC AAC ACG ATC T- 
(TAMRA)230). Total DNA was extracted from BALB/c nude murine samples (tumors, livers, blood) 
using the QIAamp DNA Blood Mini K it (Qiagen, Hilden, Germany) according to manufacturer’s 
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protocol. Subsequently isolated DNA was analyzed for adenoviral E4 copy number normalized to 
murine beta-actin (liver, blood) and human beta-actin (tumor), respectively ((primer FW: 50-CGA 
GCG GTT CCG ATG C-30, primer RV: 50-TGG ATG CCA CAG GAT TCC AT-30, probe murine 
beta-actin: 50-(6FAM)-AGG CTC TTT TCC AGC CTT CCT TCT TGG-(TAMRA)230; (primer 
FW: 50-CAG CAG ATG TGG ATC AGC AAG-30, primer RV: 50- CTA GAA GCA TTT GCG 
GTG GAC-30, probe human beta-actin: 50-(6FAM)- AGG AGT ATG ACG CCG GCC CCT C-
(TAMRA)230). Samples were analyzed using LighCycler qPCR machine (LighCycler 480, Roche, 
Basel, Switzerland). 
 
Histopathological studies 
Left lateral lobe of liver, half of spleen and one lobe of lungs were taken into 4% buffered formalin at 
necropsy. Finnish Centre for Laboratory Animal Pathology, Helsinki, Finland performed the 
histopathological evaluations of the lung, liver, spleen and tumor in vivo samples of nude (athymic) 
mice, implanted with human tumor xenograft and treated with virus alone, control EVs and EV-
Virus-PTX by histotechnology. The samples were embedded into paraffin, cut at 4 µm (spleen 3 μm), 
and stained with haematoxylin and eosin. The histopathological evaluation was performed as a blind 
using 40x magnification using the microscope Zeiss Axio Imager.A2, Carl Zeiss Microscopy GmbH, 
Jena, Germany.  
 
 
 Total RNA-sequencing 
 
RNA from tumor tissues, from mice treated with control EVs, EV-Virus and EV-Virus-PTX, were 
extracted using RNeasy Plus Micro Kit (Q iagen) according to the manufacturer’s instructions. 
Indexed libraries were prepared from 10 ng/ea purified RNA with SMARTer Stranded Total RNA-
Seq Kit - Pico Input Mammalian (Clontech Laboratories, Inc.) according to the manufacturer’s 
instructions. Libraries were quantified using the TapeStation 4200 (Agilent Technologies) and pooled 
such that each index-tagged sample was present in equimolar amounts, with final concentration of the 
pooled samples of 2nM. The pooled samples were subject to cluster generation and sequencing using 
an Illumina NextSeq 500 System (Illumina) in a 2x150 single read format at a final concentration of 
1.8 pmol.  
 
RNA-Seq Analysis 
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The raw sequence files generated (fastq files) underwent quality contro l analysis using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  To analyze RNA-Seq data we used the 
strategy called "Direct mapping" as previously described [36]. Reads were first mapped on human 
genome (assembly hg38) using STAR [37]. The quantification of transcripts expressed for each 
replicate of the sequenced samples was performed using HTSeq-count [38]. R was used to create a 
matrix of all transcripts expressed in all samples with the corresponding read-counts and the 
Bioconductor package limma [39] was used to normalize the data and then to perform the d ifferential 
expression analysis: an Empirical Bayes moderation t test was performed.  Data were also normalized 
in FPKM (Fragments Per Kilobase Of Exon Per Million Fragments Mapped) using Cuffnorm [40]. 
Genes up-regulated (log2FC>=1) and down-regulated (log2FC<=-1) with a P-value<0.05 were 
selected as differentially expressed. From these lists of DEGs, Genesis software [41,42]  was used to 
generate heat maps and to investigate the gene ontology (GO) terms in the two gene sets of 
differentially expressed genes.  
 
Statistical analysis 
 
Statistical analysis was performed by using one-way ANOVA followed by Bonferroni post-hoc test . 
Survival curves and their statistical analysis were performed using Kaplan–Meier test. The in vitro 
therapeutic synergy was calculated using fractional tumor cell viability (FTV) method[43,44]. 
Adjusted P-values in Supplementary Table 3 were calculated performing Fisher’s exact test and the 
correction for multiple hypothesis testing using the Benjamini-Hochberg method [45]. All statistical 
analysis, calculations and tests were performed using GraphPad Prism 5 (GraphPad Software, San 
Diego, CA). 
 
RESULTS 
Oncolytic adenoviruses can be encapsulated inside EVs with PTX  
     For investigating the possibility to create a new type of systemic drug delivery strategy for lung 
cancer, we encapsulated chemotherapy drug and oncolytic virus into EVs. The size distributions of 
EV-Virus and EV-Virus-PTX formulations were determined by using NTA (Figure 1AB). Size 
distribution of both control EVs and EV-Virus formulations were detected to be in the range of 50- 
1000 nm. The size distribution of EV-Virus overlaps with the size of the Virus (93.8 ± 4.3 nm) with 
most of the EVs being smaller  or the same size as the virus (Figure 1A). In addition even though 
heating was used to inactivate any free viruses in samples, the inactivated free virus particles are still 
present and this may affect the size distribution of EV-Virus, bringing it closer to the size distribution 
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of free virus (Figure 1A). The effect of heating on the size distribution of EVs was also assessed with 
A549 control EVs: while the particle count of heated EVs was within the standard error of non-boiled 
EVs, the size distribution shifted to slightly smaller (approximately 20 nm) after boiling, which can 
affect the result of EV-Virus as well (unpublished data not shown). In any case, the size distributions 
of EV-Virus and control EVs were very similar, with EV-Virus being slightly more oriented towards 
its peak at 75 nm. With EV-Virus-PTX and EV-PTX (EVs loaded with PTX), no significant size 
differences were seen due to the addition of PTX (Figure 1B). Furthermore, control EVs and EV-
Virus both had a similar strongly negative zeta-potential of approximately -40 mV, while the free 
virus had a zeta-potential of -20 mV (Figure 1C), suggesting that EV-Virus preparation consisted 
mostly of EVs, otherwise it zeta-potential should have shifted towards a less negative value. The 
zeta-potential was also unaltered in EV-Virus-PTX, and EV-PTX formulations, as is to be expected 
since PTX is a chargeless molecule (Figure 1C). 
      Helium Ion Microscopy (HIM) is an imaging technique comparable to Scanning Electron 
Microscopy, with the distinction that samples do not require conductive coating. HIM was used to 
image uninfected cells as well as EV and EV-Virus infected cells in an attempt to observe potential 
changes due to the EV-Virus interactions on the cell surface. EV exposed cells did not appear to 
differ from the un-infected cells (results not shown). Yet, occasionally the surface of EV-Virus 
infected cells was covered with vesicle- like protrusions (Figure 1D). This phenomenon may derive 
from virus-induced changes inside the cell, resulting in phenotypic alterations on the surface. 
       The amount of PTX encapsulated into the EVs was determined by UPLC as previously described 
[23] (Supplementary Table 1). The washing protocol used in the production of EV-Virus-PTX 
formulations were successful, since the PTX concentration of the second washing step supernatant 
was below 0.05 µM, and thus insignificant when compared to the PTX concentration of EV-Virus-
PTX (4.7 µM). The UPLC assessed concentration of the 10µM PTX control sample, shows a 38 % 
loss of PTX (Supplementary Table 1). However, the concentration of the 10 mM PTX DMSO stock 
solution was confirmed by UPLC analysis. PTX precipitation is most likely not the reason for the 
PTX loss seen in the control sample, since acetonitrile was added to a final concentration of 75% to 
samples prior to UPLC analysis. However the analysis of PTX in EV-Virus-PTX was just meant as a 
qualitative proof that PTX is indeed encapsulated in the vesicles. 
  
 
 
In vitro and in vivo enhanced antitumor effect of Virus and PTX in EV-Virus and EV-Virus-PTX 
formulations 
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    The responsiveness of solid tumors to chemotherapeutic agents depends to great extent of the 
optimization of the drug delivery. As of such, we here set to evaluate in a factorial experiment the in 
vivo efficacy of several combinations of EV-Virus-PTX formulations to alter tumor growth in a lung 
xenograft animal model. Abraxane is a clinically approved nanoformulation [46] chosen according to 
the clinical settings previously described [34] and it was introduced, since previous study showed that 
patients with non small cell lung cancer may benefit from the treatment [47,48]. Nude mice bearing 
A549 cells originating tumor in the right flank were treated by intravenous (iv) injections on day 0, 2, 
4 and 15 with: i) EVs alone (1x109 particles/tumor), Virus alone (1x108 vp/tumor), Abraxane (10 mg 
of PTX/kg); Virus+Abraxane (1x108 vp/tumor + 10 mg of PTX/kg); EV-Virus (1x108 particles/tumor, 
+ 1x108 vp/tumor); EV-Virus-PTX formulation (1x108 particles/tumor including 1x108 vp/tumor, and 
10 mg of PTX/kg) (Supplementary Table 2). EVs alone were not able to control the tumor growth,  
and were thus used as negative control in our experiments. The intratumoral (it) treatment did not 
show significant differences between EV-Virus, EV-Virus-PTX and Abraxane treatments 
(Supplementary Figure 1).  
Interestingly, the iv injection of the EV-Virus-PTX formulation significantly reduced 
(P<0.001) tumor growth in comparison to naked virus and Virus+Abraxane (Figure 2A). The highest 
survival rate was observed in EV-Virus and EV-Virus-PTX treatments (90% at 60 days) (Figure 2B). 
The best survival rate (Figure 2B) was observed in the combinatory group: EV-Virus-PTX over other 
studied formulations, suggesting that the best anti-tumor efficacy response was positively correlated 
with the survival.  
The local replication of the virus was quantified by the adenovirus E4 copy number in tumor, 
liver and serum by qPCR analysis. Adenoviral particles were not detected in serum and liver in any 
of the tested groups (Figure 2C), suggesting that EV-Virus administered intraveniously infects and 
replicates only in tumor cells. 
 In order to verify the in vitro cell death by the EV-Virus and EV-Virus-PTX due to the 
apoptotic events, the flow cytometry measurements were carried out by measuring the amount of 
Annexin-V (early apoptotic stage) and propidium iodide (late apoptotic stage) for positive cells at 24 
hours post treatment. By that we were able to confirm that EV-Virus and Virus+PTX treatments 
induced both early and late in vitro apoptotic effect in A549 cells (Figure 2DE) (Supplementary 
Figure 2).  The in vitro therapeutic synergy between EVs and Virus was calculated using fractional 
tumor cell viability (FTV) method and demonstrated synergistic antitumor effect in the EV-Virus-
PTX treatment group (Figure 2FG).  
 Histopathological analysis of the liver, spleen and tumor samples from mice demonstrated no 
substantial changes (Figure 3), with the exception of EV-Virus treatment, which showed moderate-
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sized inflammatory focus (mostly neutrophils) in otherwise normal liver lobule (Figure 3A4). Spleen 
samples displayed general histological pattern typical for nude mice such as periarteriolar lymphatic 
sheet areas (PALS) and in some cases mild lymphocyte hyperplasia (Figure 3B1-B4) [49]. Tumor 
samples exhibited typical features of a lung carcinoma (malignant epithelial tumor) and they were 
very uniform in their growth pattern and cellular features (Figure 3C4). 
 
 
Oncolytic adenoviruses encapsulated in the EVs show increased transduction efficacy and 
enhanced infectious titer  
 
 The transduction assay was conducted by using the red fluorescent protein [30] expressing virus 
Ad5D24RFP encapsulated in EVs. The transduction efficacy of the virus Ad5D24RFP alone was 
compared with EV-Virus and EV-Virus-PTX.  Transduction was assessed at 8, 24 and 48 hours post-
infection. Interestingly, already at 8 hours from infection, the amount of red fluorescent cells in EV-
Virus and EV-Virus-PTX treated cultures was higher compared to cells treated with Virus 
Ad5D24RFP after 48 hours (Figure 4AB). The infectivity of the different formulations (Virus, 
Virus+PTX, EV-Virus and EV-Virus-PTX) were further investigated by Immunocytochemistry 
Assay (ICC). The infectious titer was found to be significantly higher for EV-Virus and EV-Virus-
PTX formulations when compared to cells treated with virus Ad5D24RFP alone or with Virus +PTX 
(Figure 4CD). 
 
 
 
Oncolytic adenoviruses encapsulated in the EVs show enhanced cytotoxicity  
 
     To ensure that the cancer derived EVs did not affect healthy cells at least during the period of 48-
96 hours, in which we saw a clear anticancer effect in cancer cells, we performed the experiments 
also with the PNT2 cells, which is a non-cancerous cell line of prostate epithelium. It was shown by 
MTS cell viability assay (Figure 5A).  
    Then cytotoxicity of the EV-formulations was studied by MTS cell viability assays on the A549 
cell line. EV-Virus and EV-Virus-PTX formulations reduced cell viability significantly more when 
compared to cells treated with the virus alone (Figure 5B) (p<0,001). Indeed, the cell killing activity 
of EV-Virus and EV-Virus-PTX formulations was investigated by the MTS cell viability assays on 
A549 and PC3 cell lines treated with samples obtained from PC3 and A549 cells, respectively. The 
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EV-formulations obtained from PC3 cells (EVs, EV-PTX, EV-Virus, EV-Virus-PTX) have been 
used to treat A549 cells, while EV-formulations obtained from A549 cells (EVs, EV-PTX, EV-Virus, 
EV-Virus-PTX) have been used to treat PC3 cells in order to carry out the cross-experiments. In both 
experiments, it was observed that the cell killing effect of the EV formulations is not cancer cell line 
dependent (Figure 5CD) (p<0,001). 
 
 
Different molecular mechanisms underlying the anti-neoplastic effects produced by EV-Virus and 
EV-Virus-PTX treatments  
For the evaluation of the molecular mechanisms underlying the enhanced antitumor effect 
observed between viral and paclitaxel treatments delivered with EVs, we carried out an RNA-SEQ 
transcriptomic analysis on the RNAs extracted from tumor xenografts grown in EV, EV-Virus and 
EV-Virus-PTX treated mice. The analysis was carried out for 3 samples/group with the only 
exception of the EV-Virus group for which only 2 samples were of sufficient quality to be analyzed 
due to the small ratio of human versus mouse mRNA extracted from the xenograft. The analysis 
identified 615 and 317 transcripts for EV-Virus-PTX and EV-Virus treatments, respectively, as 
differentially expressed in the two conditions, when compared to the EV contro l treatment. Most of 
the differentially expressed genes were up-regulated in the EV-Virus, while the majority were down-
regulated in the EV-Virus-PTX groups (Figure 6A). Among the differentially expressed genes only 
47 were differentially modulated by both treatments (Figure 6B) as also detailed in the heat-maps 
(Figure 6C). The two distinct genetic programs triggered by EV-Virus and EV-Virus-PTX indicated 
that a differential cellular response was produced by the two treatments. Indeed, although the types of 
biological processes involved in the response appeared remarkably similar for both treatments 
(Supplementary Table 3), the genes dysregulated were different. A general consideration on the net 
effect produced by the differential expression in terms of up- and down-regulation of each pathway is 
somehow hampered by the complexity of signals like “metabolic process” or “cellular component 
organization”. However, were the analysis was possible like for example for the mitogenic pathway, 
it was clear that both treatments triggered an anti-cancer effect while regulating different set of genes 
(Supplementary Figure 3). In the mitogenic pathway, for example among the genes modulated by 
EV-Virus-PTX treatment, USP37, SNX33 and POLE were down regulated, whereas overexpression 
of these genes was shown to induce proliferation by promoting G1/S phase transition [50]; S-phase 
progression and mitosis respectively [51]. A net anti-proliferative effect was suggested also 
considering the genes differentially expressed by the EV-Virus treatment, which involves down 
regulation of BRSK2 expression, known to increase the percentage of cells in G2/M when 
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overexpressed [52], and the upregulation of E2F4, a factor negatively influencing the G1 progression 
through cell cycle [53]. In conclusion, our transcriptomic analysis suggested that the addition of PTX 
in the therapeutic EV-Virus-PTX complex is inducing a novel anti-tumor mechanism, which is likely 
the basis of the observed enhanced  in vivo antitumor effects and  in vitro synergistic effect. 
 
 
DISCUSSION  
  
Despite the improvements made in the last years in early detection methods and treatment 
modalities, lung cancer is still often diagnosed at an advanced stage with poor prognosis and 
inefficient treatment options [54]. Oncolytic viruses form a potentially powerful anticancer tool, 
especially when used in combination with other antitumor agents, for advanced cancer patients 
[14,15].  The systemic delivery of oncolytic viruses is a key factor in order to allow the agent to reach 
disseminated tumor deposits [55]. However, many early clinical trials have failed since low attention 
was focused to the features of the delivery process [56]. One possibility is to combine oncolytic 
viruses with nanoparticle delivery approaches since in systemic delivery, targeting with nanoparticles 
may focus the viral load to both primary and metastatic tumors to ensure an efficient initial infection 
[57].  Even if current studies have emphasized intratumoral delivery, the systemic delivery seems to 
be required for the treatment of metastatic cancer [58]. The intratumoral injection of viruses and 
therapeutic agents has also disadvantages due to the low efficacy and the inability to treat solid and 
metastatic tumors where the systemic delivery is required [6] [59].  
       Our system represents a strategy for the systemic delivery of both oncolytic virus and paclitaxel 
by the cancer cells originated EVs. Herein, the use of cancer-derived EVs represented a proof-of-
concept model, since functional studies showed that cancer cells originated EVs have specific cell 
tropism to their own tumors [60]. However other major challenges for the EVs therapeutic 
applicability remain, such as the short circulation time of intravenously injected EVs and the possible 
unspecific accumulation in liver and lung. Given that, to possibily increase the circulation time and 
have possible involvement in tumor accumulation, it was proposed a post- insertion of EVs with 
nanobody PEG-micelles as a promising tool for the EVs accumulation in targeted tissues and to 
improve their potential use in drug delivery [61]. Although EVs have multiple advantages when 
exploited as a drug delivery vehicles [62,63], due to their role as regulators in intercellular 
communication [64,65], there is still limited knowledge related to scalable isolation, purification 
methods, as well as criteria for quality analyses of EV-based therapeutics [24,27,66,67]. According to 
the minimal information for studies of EVs (MISEV), the selection of a method for isolation and 
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purification should be focused on the scientific question and down-stream steps [68]. However, we 
have set up a system where EVs are produced by large-scale two compartments bioreactor to reduce 
the workload of EVs production.   
      Indeed it has been shown that cells use EVs to remove harmful DNA, including DNA originating 
from adenoviral infection, as a mechanism to protecet themselves [69]. This and our observations 
raise the question, whether there exist EVs from infected cells that carry only viral DNA without the 
viral capsid, therefore acting as an alternative delivery vector for the viral DNA for infection, where 
also the size of the EVs versus Virus becomes irrelevant. However as it has not been clarified until 
this moment, we cannot further comment on this alternative in the light of our current study, however 
this aspect should be investigated further.  
       Recently, an increased transduction efficiency for adenoviral vectors encapsulated in anionic 
liposomes via calcium-induced phase-change was reported [70]. Based on this incentive, we checked 
whether oncolytic viruses expressing red fluorescent protein encapsulated into the EVs (either with or 
without loaded PTX) have an effect on the transduction efficacy. Notably, already at 8 hours post-
infection the EV-Virus and EV-Virus-PTX complex groups showed enhanced transduction efficacy 
in comparison to naked virus as measured by the number of fluorescent cells over other groups.  EV-
Virus and EV-Virus-PTX complexes also appear to have greater infectivity than virus alone, 
according to the assay for the infectious titer, which, to some extent, is dependent on the higher 
efficiency of virus entry into the lung cancer cell line [71] and, since the transduction was enhanced, 
it has an impact on the improved infectivity.   
       These results suggest that EVs can greatly improve the delive ry of oncolytic viruses to tumor 
cells.   Further, EV-infected cells, as well as cells infected by the conventional route, will produce not 
only viruses but also EV-Virus complexes that can subsequently infect other tumor cells in its 
vicinity. Accordingly, the surfaces of EV-Virus infected cells were covered with vesicle- like 
protrusions while a similar phenotype was absent in uninfected cells. This phenotype may partly 
derive from virus- induced vesicle formation during apoptosis. Indeed it is still not clear at which 
apoptotic stage these protrusions have been observed since this phenotype did not always appear, 
however when it did, it was there at least after 24 hours post- infection. In the future, it would be 
important to characterize the proteome from those vesicles that enclose virus particles in order to 
determine whether they have unique constituents or if their contents match to those of apoptotic 
bodies or other types of EVs. Also, given the efficacy of EV-mediated transduction, it could be 
possible that (non-enveloped) viruses, or probably just their naked genomes, may spread via EVs 
within the host organism. Combined treatment of oncolytic adenovirus and paclitaxel have been 
shown to have significantly higher efficacy both in vitro and in vivo in comparison to oncolytic virus 
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therapy alone [17,72,73]. The role of paclitaxel in EV-Virus-PTX complex was to enhance anticancer 
effect when combined with oncolytic adenoviruses and finally encapsulated into the EVs. We 
hypothesized that combined agents into the same formulations could exhibit even stronger anticancer 
effect, as it is known that oncolytic adenoviruses are novel antitumor agents with the ability to 
selectively replicate in and lyse cancer cells while being harmless for the rest of the body [74] and 
paclitaxel, an antitumor drug that plays a key role in cancer chemotherapy  [75]. 
It has been already reported that the intratumoral injection of paclitaxel reduces tumor growth 
in A549 tumor xenograft mice [76]. Additionally, it has been demonstrated that PTX-loaded EVs are 
more effective in inhibiting the growth of Lewis lung carcinoma metastases than Taxol, a commercial 
formulation of PTX [77]. Given especially the here-demonstrated increased antitumor efficacy in 
vivo, the combination of paclitaxel and adenovirus in our EV-formulation based delivery approach 
should similarly exhibit stronger in vitro anticancer effect. In order to evaluate possible improved 
antitumor effect, in local and systemic delivery, we studied the anti-tumor activity of Virus alone, 
and Virus-PTX encapsulated into EVs, in a lung cancer xenograft model using both intratumoral (i.t.) 
and intravenous injection (i.v.). I.t. administration of EV-Virus-PTX resulted in tumor growth 
reduction. Interestingly systemic (i.v.) administration exhibited even stronger antineoplastic activity 
in lung cancer xenograft mouse model. This is in line with previous experiments showing that 
intravenous treatment of EV loaded with chemotherapeutic agents can be effective [78]. Importantly, 
at the end point which was not due to death, metastasis were not macroscopically observed in 
xenograft murine organs [79]. Furthermore any abnormal clinical signs were observed during the 
study. Indeed, we found that EV-Virus-PTX was able to induce apoptosis and necrosis showing 
synergistic antitumor effect in vitro.  
   In turn, based on the in vitro cancer cell cross-experiment studies with the PC3 and A549 we 
have observed that the cancer cell origins of EVs does not have impact on cancer cell EV delivery 
properties and killing efficacy in at least the two cancer types used. Our cancer cell cross-experiment 
results are preliminary; however, they showed, that independently of the origin of the cancer cell line 
EVs used, they are effective in both cases. This suggests, that the EVs as drug carriers could have 
versatile applications. Furthermore, the EV-Virus-PTX formulation was able to locally replicate 
inside tumor, suggesting that viruses administered within EVs could indeed act as self- renewing drug 
in situ, making them especially lucrative candidates for treating metastatic cancer since any 
metastatis were detected in our in vivo animal experiments. However, even if an absolute comparison  
between virus treatments and EV treatments is not possible with the strategy we used, we find that it 
can be used to make a conservative comparison for the amounts of viral and EV particles since we 
did not have more EVs compared to the virus control, and since EV-Virus and EV-Virus-PTX 
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treatments were more effective, this result cannot therefore be explained by a higher dose compared 
to the virus control. 
The molecular mechanism underlying the ability of PTX to enhance the anticancer effect produced 
by the virus administered in combination with EVs is far from being identified: however, our RNA-
SEQ analysis provides some insights showing for the first time that a differential anti-neoplastic 
mechanism is operating when virus is alone in comparison to being together with PTX in the 
therapeutic complex. Indeed, PTX was not just contributing with additional gene regulation, but was 
completely changing the intracellular nodes of the cancer-related pathways targeted by the treatment. 
Transcriptomic differences observed between EV-Virus and EV-Virus-PTX groups may reflect 
differences in treatment schedule, however we believe it is very unlikely that an additional fourth 
treatment with EV-Virus alone at day 15 would produce the enhanced effect on tumor growth 
observed in the EV-Virus-PTX group; an additional treatment with EV-Virus was expected to 
produce an additive effect, thus, we consider a better explanation for the enhanced effect the presence 
of PTX in the formulation,. Future studies are needed to investigate the reasons why PTX in the 
complex is able to change these intracellular targets thus creating the condition for the enhanced 
antitumor effect.  
 
 
 
Conclusions 
As a proof of concept, we have demonstrated that cancer cell-derived EVs could be useful vehicles 
for systemic drug delivery of oncolytic viruses and paclitaxel in the treatment of lung cancer.  
We showed that an autologous EV-mediated delivery provides a selective cancer cell tropism and  
contributes to enhancing PTX anticancer effects in vitro and in vivo. Finally, our transcriptomic data 
suggested that a novel cellular response is triggered by the encapsulation of PTX in the EV-Virus 
formulation. This response blocked more sensitive nodes in cancer relevant pathways and may thus 
explain enhanced antitumor effect. All together our study strongly supports the systemic 
administration of EV-Virus-PTX formulation as new therapeutic strategy aimed at treating lung 
cancer.  
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Figure’s legends  
 
Figure 1 Oncolytic adenovirus encapsulated into the Extracellular vesicle allows complex formation. (A-B) Size 
distribution of virus alone, EV-v irus, EV-paclitaxel, EV-Virus-paclitaxel and Virus were determined by using Nano 
tracking analysis (NTA). (C) The surface charge of the virus alone, EV-virus, EV-paclitaxel, EV-Virus-paclitaxel and 
Virus was measured using ZetaSizer Nano Malvern. (D) Helium Ion Microscopy pictures imaged with Orion NanoFab 
Helium Ion Microscope (Zeiss, Germany) using 30 kV acceleration voltage with beam current 0.2-1 pA. Images are of 
non-infected (left ) and EV-V infected (right) cells. The deformed phenotype with multip le protrusions extending from the 
cell surface was often observed in infected cells  at least after 24h post-infection. 
 
Figure 2  In vitro and in vivo enhanced antitumor  effects of oncolytic virus and paclitaxel encapsulated in 
Extracellular vesicles for lung cancer treatment.  (A) A549 cell line was implanted subcutaneously into the right flank 
of BALB/c nude mice. All treatments were admin istered intravenously (i.v.). Tumor growth was fo llowed over time. (B) 
Kaplan-Meier test was used to calculate the survival profile. (C) Adenoviral copies toward  E4 gene were measured by 
qPCR from euthanized  mice’s organs (tumor, liver and serum) at  the end of the treatment. (D-E) Early  and late apoptotic 
or necrotic cell death were measured in A549 cells after 24 hours post-treatment. The amount of early and late apoptotic 
or necrotic cells were analyzed by flow cytometry  24 hours after the treatments. FITC-labeled Annexin-V was used to 
indicate the early apoptotic cell and PI for the necrotic or late apoptotic cells, ***P < 0.001. (F-G) The assessment of the 
in vitro therapeutic synergy was calculated with FTV method. Observed FTV (mean value of experimental cell 
viability)/(mean value of cell viab ility control). Expected FTV (mean FTV of Experimental condition)/(mean FTV of 
experimental control). A ratio >1 indicates a synergisti  effect, and a ratio <1 indicates a less than additive effect). 
 
Figure 3 : Histopathological examination on liver, s pleen and tumor. (A-C) Liver samples from mice treated with 
Virus (A1), EVs  (A2), EV-Virus-PTX (A3) or EV-Virus (A4) exh ibited no significant histopathological findings.  A liver 
sample from an  EV-Virus -treated mouse (A4) shows a background lesion; a moderate-sized  inflammatory focus (mostly 
neutrophils; arrow) in otherwise normal liver lobule. (B1) Sp leen samples from mice treated with virus alone exhib it mild 
lymphocyte  hyperplasia (lymphatic follicles with lymphoblast-like cells, mitotic figures and tingible body macrophages), 
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while spleen samples (B2) from mice t reated with extracellu lar vesicles alone show no significant findings. Typical for 
nude mice, the PALS area (lightly-staining zone in white pulpa surrounding blood vessels) is sparse and marg inal zone 
inconspicuous. In addition, no secondary follicles are present. (B3) A representative spleen sample from a mice treated 
with EV-Virus-PTX d isplays mild hyperplasia of the marginal zone without lymphatic hyperplasia and a sample (B4) 
from mouse treated with EV-Virus mild hyperplasia of the marginal zone with mild lymphocyte hyperplasia. (C1) Tumor 
samples from mice treated with virus alone show necrotic remnants of cells in a s mall necrotic area and apoptotic cell 
remnants in degenerative area. (C2) A large cav ity is filled with proteinacous fluid and lined by cubic to flattened cell. No 
necrosis. Tumor capsule (C3) A tumor sample treated with EV-Virus-PTX exhib its a large cavity with intraluminal blood 
and proteinacous fluid.  Tumor tissue grows in densely packed nests or packets, and peripheral c ords. No necrosis is 
present. (C4) Tumor sample treated with EV-Virus displays large number of neutrophils (arrowheads; examples) among 
foamy neoplastic cells. 
 
Figure 4: Effect of oncolytic adenovirus encapsulated into extracellular vesicles on cell transduction and infectivi ty . 
(A) The transduction efficacy was evaluated by infection with an oncolyitc adenovirus encoding for the red fluorescent 
protein (RFP) encapsulated into the extracellu lar vesicles loaded or not with PTX.   RFP was measured using Varioskan 
plate reader after 8, 24 and 48h post infection, *** P<0.001. (B) Most representative fluorescent microscope photograph 
(400μm) of the infected cells. (C) The infectiv ity of virus alone, Virus+PTX, EV-Virus and EV-Virus-PTX were assessed 
by ICC assay. (D) Most representative microscope photographs (400μm) of the infected wells are presented. Figures 
represent difference in hexon protein expression (virus assembling), without distinguishing infectivity, replication, or 
gene expression manner , *** P<0.001.    
 
 
 
 
 
Figure 5 Effect of oncolytic adenoviruses encapsulated into extracellular vesicles on cell viability. (A-B) Cell 
viability was performed by MTS assay on PNT2 and A549 cell lines. The absorbance was measured with a 96 -wells plate 
spectrophotometer Varioskan Flash Multimode Reader at 490 nm. (C-D) Cell v iability was performed by MTS assay on 
A549 and PC3, respectively treated with samples from PC3 cells and A549 cell lines. EV-formulat ions from PC-3 cell 
line tested in A549 cell line: control EVs , EV-PTX, EV-Virus, EV-Virus-PTX. Other formulations tested in A549 cell 
line: Virus alone, PTX, Virus+PTX. EV-formulat ions from A549 cell line tested in PC-3 cell line: control EVs, EV-PTX, 
EV-Virus, EV-Virus-PTX. Other forumulations tested in PC-3 cell line: Virus alone, PTX, Virus+PTX.  
The absorbance was measured with a 96-wells plate spectrophotometer Varioskan Flash Multimode Reader at 490 nm. 
 
 
Figure 6 Transcriptomic analysis .  (A) The gene expression profile is represented as heat map  (red, high relat ive 
expression; black, mean expression; green, low relat ive expression) showing the expression of up - and down-regulated 
genes for EV-Virus (615 t ranscripts) and EV-Virus-PTX (317 transcripts) treatment group, each compared to  EV 
treatment. (B) Venn diagram showing the number of unique and common  (47) genes differentially expressed in the EV-
Virus and  EV-Virus-PTX treatment groups. (C) Heat map  showing the expression of 47 common genes subdivided 
according to the GO terms (Cellular Processes). Sample/group : EV n=3, EV-Virus n=2, EV-Virus-PTX n=3.. Cell cycle, 
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cell communicat ion, metabolic process, cell death, gene expression and cellular component organization are the 
categories with high level of overlapping (number of common genes more than 5). 
 
Supplementary Figure 1. In vivo efficacy study in lung cancer xenograft animal  model using intratumoral injection. 
Nude BALB/c bearing A549 tumors were treated intratumorally  with tested items EV-Virus-PTX (1x10
8 
particles/tumor, 
1x10
8
 vp/tumor, 10 mg/kg);  EV-Virus (1x10
8 
particles/tumor, 1x10
8
 vp/tumor); Abraxane (10 mg/kg); Virus 1x10
8
 
vp/tumor; EV 10
9 
particles/tumor; Virus+Abraxane (1x10
8
 vp/tumor and 10 mg/kg) . Dosing days were 0, 2, and 4 for 
Virus and EV-Virus; 0 and 15 for Abraxane; 0,2,4 and 15 for EV and EV-Virus-PTX . Tumor growth was measured over 
time.  
 
 
Supplementary Figure 2. Induction of apoptotic and necrotic cell death. (A-B) Early and late apoptotic or necrotic 
cell death were measured in  A549 cells after 24 hours post-treatments. The amount of early  and late apoptotic or necrotic 
cells 24 hours after treatments were analyzed by flow cytometry. FITC-labeled Annexin-V was used to indicate the early 
apoptotic cell and PI for the necrotic or late apoptotic cells. , P < 0.001. 
 
Supplementary Figure 3. Cell cycle genes differentially regulated by EV-Virus and EV-Virus-PTX treatments . The 
scheme maps the cell cycle genes involved in the regulation of G1/S/G2/M cell phases, that are up (in red) and down-
regulated (in green) in  the EV-Virus-PTX and EV-Virus treatment groups compared to EVs  alone.  Adjusted P-values 
were calculated performing Fisher’s exact test and the Benjamini-Hochberg correction. 
 
Supplementary Table 1. Quanti fication of paclitaxel concentration. UPLC determined paclitaxel concentration (C0) 
of an EV-Virus-PTX stock preparation and the associated controls  
 
 
Supplementary Table 2.  (A) Study design using systemic injection. (B) Study design using intratumoral injection. 
 
 
Supplementary Table 3: Gene Onthology categories within cellular processes. (A-B) Tables show the gene onthology 
cellular process terms found enriched for our genes by using Ensembl GO DataBase  within Genesis software. 
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